MDPI and ACS Style
Grandal, B.; Mangiardi-Veltin, M.; Laas, E.; Laé, M.; Meseure, D.; Bataillon, G.; El-Alam, E.; Darrigues, L.; Dumas, E.; Daoud, E.;
et al. PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. Cancers 2021, 13, 746.
https://doi.org/10.3390/cancers13040746
AMA Style
Grandal B, Mangiardi-Veltin M, Laas E, Laé M, Meseure D, Bataillon G, El-Alam E, Darrigues L, Dumas E, Daoud E,
et al. PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. Cancers. 2021; 13(4):746.
https://doi.org/10.3390/cancers13040746
Chicago/Turabian Style
Grandal, Beatriz, Manon Mangiardi-Veltin, Enora Laas, Marick Laé, Didier Meseure, Guillaume Bataillon, Elsy El-Alam, Lauren Darrigues, Elise Dumas, Eric Daoud,
and et al. 2021. "PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy" Cancers 13, no. 4: 746.
https://doi.org/10.3390/cancers13040746